287 related articles for article (PubMed ID: 26802025)
21. Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer.
Razmara AM; Farley LE; Harris RM; Judge SJ; Lammers M; Iranpur KR; Johnson EG; Dunai C; Murphy WJ; Brown CT; Rebhun RB; Kent MS; Canter RJ
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631708
[TBL] [Abstract][Full Text] [Related]
22. GSK3 Inhibition Drives Maturation of NK Cells and Enhances Their Antitumor Activity.
Cichocki F; Valamehr B; Bjordahl R; Zhang B; Rezner B; Rogers P; Gaidarova S; Moreno S; Tuininga K; Dougherty P; McCullar V; Howard P; Sarhan D; Taras E; Schlums H; Abbot S; Shoemaker D; Bryceson YT; Blazar BR; Wolchko S; Cooley S; Miller JS
Cancer Res; 2017 Oct; 77(20):5664-5675. PubMed ID: 28790065
[TBL] [Abstract][Full Text] [Related]
23. Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment.
Oyer JL; Pandey V; Igarashi RY; Somanchi SS; Zakari A; Solh M; Lee DA; Altomare DA; Copik AJ
Cytotherapy; 2016 May; 18(5):653-63. PubMed ID: 27059202
[TBL] [Abstract][Full Text] [Related]
24. Synergistic cytotoxicity of interferonalpha-2b and interleukin-2 in combination with PBMC against ovarian cancer: development of an experimental model for cellular therapy.
Ingersoll SB; Patel S; Caballero L; Ahmad S; Edwards D; Holloway RW; Edwards JR
Gynecol Oncol; 2009 Jan; 112(1):192-8. PubMed ID: 18995891
[TBL] [Abstract][Full Text] [Related]
25. Selection and expansion of natural killer cells for NK cell-based immunotherapy.
Becker PS; Suck G; Nowakowska P; Ullrich E; Seifried E; Bader P; Tonn T; Seidl C
Cancer Immunol Immunother; 2016 Apr; 65(4):477-84. PubMed ID: 26810567
[TBL] [Abstract][Full Text] [Related]
26. hIL-15-gene modified human natural killer cells (NKL-IL15) exhibit anti-human leukemia functions.
Jiang W; Zhang C; Tian Z; Zhang J
J Cancer Res Clin Oncol; 2018 Jul; 144(7):1279-1288. PubMed ID: 29737430
[TBL] [Abstract][Full Text] [Related]
27. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
28. Sufficiently activated mature natural killer cells derived from peripheral blood mononuclear cells substantially enhance antitumor activity.
Liu C; Li Y; Li Y; Hu M; Wang H; Lu S; Li Z; Dilimulati D; Jiao S; Lu S; Zhao W
Immun Inflamm Dis; 2024 Jan; 12(1):e1143. PubMed ID: 38270321
[TBL] [Abstract][Full Text] [Related]
29. Visualization of effective tumor targeting by CD8+ natural killer T cells redirected with bispecific antibody F(ab')(2)HER2xCD3.
Scheffold C; Kornacker M; Scheffold YC; Contag CH; Negrin RS
Cancer Res; 2002 Oct; 62(20):5785-91. PubMed ID: 12384539
[TBL] [Abstract][Full Text] [Related]
30. A Wilms tumor cell line, HFWT, can greatly stimulate proliferation of CD56+ human natural killer cells and their novel precursors in blood mononuclear cells.
Harada H; Watanabe S; Saijo K; Ishiwata I; Ohno T
Exp Hematol; 2004 Jul; 32(7):614-21. PubMed ID: 15246157
[TBL] [Abstract][Full Text] [Related]
31. Human IL-15 Inhibits NK Cells Specific for Human NK-92 Cells.
Bergman H; Lindqvist C
Anticancer Res; 2021 Jul; 41(7):3281-3285. PubMed ID: 34230122
[TBL] [Abstract][Full Text] [Related]
32. Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer.
Ingersoll SB; Ahmad S; McGann HC; Banks RK; Stavitzski NM; Srivastava M; Ali G; Finkler NJ; Edwards JR; Holloway RW
Mol Cell Biochem; 2015 Sep; 407(1-2):281-7. PubMed ID: 26048718
[TBL] [Abstract][Full Text] [Related]
33. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
34. IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.
Evans R; Fuller JA; Christianson G; Krupke DM; Troutt AB
Cell Immunol; 1997 Jul; 179(1):66-73. PubMed ID: 9259773
[TBL] [Abstract][Full Text] [Related]
35. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
36. hIFN-α gene modification augments human natural killer cell line anti-human hepatocellular carcinoma function.
Jiang W; Zhang C; Tian Z; Zhang J
Gene Ther; 2013 Nov; 20(11):1062-9. PubMed ID: 23759701
[TBL] [Abstract][Full Text] [Related]
37. Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer.
Hermanson DL; Bendzick L; Pribyl L; McCullar V; Vogel RI; Miller JS; Geller MA; Kaufman DS
Stem Cells; 2016 Jan; 34(1):93-101. PubMed ID: 26503833
[TBL] [Abstract][Full Text] [Related]
38. Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15.
Imamura M; Shook D; Kamiya T; Shimasaki N; Chai SM; Coustan-Smith E; Imai C; Campana D
Blood; 2014 Aug; 124(7):1081-8. PubMed ID: 25006133
[TBL] [Abstract][Full Text] [Related]
39. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy.
Guven H; Gilljam M; Chambers BJ; Ljunggren HG; Christensson B; Kimby E; Dilber MS
Leukemia; 2003 Oct; 17(10):1973-80. PubMed ID: 14513047
[TBL] [Abstract][Full Text] [Related]
40. Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy.
Yang HG; Kang MC; Kim TY; Hwang I; Jin HT; Sung YC; Eom KS; Kim SW
J Immunother Cancer; 2019 May; 7(1):138. PubMed ID: 31126350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]